Search
Sebetralstat
go.drugbank.com/drugs/DB18305ApprovedInvestigationalSebetralstat is the first and only oral on-demand treatment for HAE, providing a convenient alternative to injectable therapies that have been challenging for patients to use [L53538, A274293]. … This plasma kallikrein inhibitor works by reducing bradykinin, the substance that causes the characteristic swelling in HAE attacks [L53533]. The U.S.
Dapsone
go.drugbank.com/drugs/DB00250ApprovedInvestigationalA sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae.
Categories: Antiinfectives for Systemic Use, Anti-Acne Preparations for Topical UseOmidenepag isopropyl
go.drugbank.com/drugs/DB15071Approved[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl.[L43503] … The use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost].
Pantoprazole
go.drugbank.com/drugs/DB00213ApprovedInvestigationalPantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme … [FDA Label] Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread.
Latanoprost
go.drugbank.com/drugs/DB00654ApprovedInvestigational[A184493] It has been found to be well-tolerated and its use does not normally result in systemic adverse effects like other drugs used to treat elevated intraocular pressure, such as [Timolol]. … It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment.
Talc
go.drugbank.com/drugs/DB09511ApprovedInvestigationalAlthough talc has been widely used for decades, lawsuits that have come to the surface claim serious health complications linked to its use. … In fact, recent studies have reported that talc increases the risk of ovarian and endometrial cancers by approximately 30 percent.
Pembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026] … [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1.
Selenium Sulfide
go.drugbank.com/drugs/DB00971ApprovedSelenium Sulfide is an antifungal agent as well as a cytostatic agent, slowing the growth of hyperproliferative cells in seborrhea. Selenium Sulfide is the active ingredient often used in shampoos for the treatment of dandruff, seborrhei...
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseBerahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalThis combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications
Regramostim
go.drugbank.com/drugs/DB05386InvestigationalRegramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages.